Medigen Vaccine Biologics (6547 TWO) stock market data APIs
NT$40.9955
1.7(4.1%)
as of July 14, 2025
Try our APIs with
free plan!
Medigen Vaccine Biologics Financial Data Overview
Price chart is built with
Anychart
Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for the treatment of influenza viruses. The company also develops dengue vaccines, which has completed Phase II clinical trial to treat dengue; anti respiratory syncytial virus (RSV), which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19. Medigen Vaccine Biologics Corporation was incorporated in 2012 and is headquartered in Zhubei City, Taiwan. Medigen Vaccine Biologics Corporation is a subsidiary of Medigen Biotechnology Corp.
Prev. Close
40.9955
Open
42.6927
High
42.0107
Low
40.9955
52 wk Range
33.7-56.6
Market Cap
13 512 M
Shares Outstanding
329 M
Revenue
662 M
EPS
-0.06
Beta
0.948
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Medigen Vaccine Biologics data using free add-ons & libraries
Get Medigen Vaccine Biologics Fundamental Data
Medigen Vaccine Biologics Fundamental data includes:
- Net Revenue: 662 M
- EBITDA: 48 063 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-15
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Medigen Vaccine Biologics News
New
Dynavax (DVAX) Gains as Medigen Rolls Out COVID-19 Vaccine
Shares of Dynavax Technologies Corporation DVAX jumped 14.4% after its Taiwan-based partner Medigen Vaccine Biologics Corporation announced the rollout of its COVID-19 vaccine — MVC-COV1901 — in t...
Powered By Dynavax Adjuvant, Medigen COVID-19 Vaccine Launched In Taiwan
Medigen Vaccine Biologics Corporation and Dynavax Technologies Corporation (NASDAQ: DVAX) announced the rollout of their COVID-19 vaccine, MVC-COV1901, in Taiwan. Approximately 600,000 people are anti...
Taiwan's Medigen to start late-stage clinical trial for COVID-19 vaccine in Paraguay
TAIPEI, July 20 (Reuters) - Taiwan's Medigen Vaccine Biologics Corp said on Tuesday it will start a late-stage clinical trial this year in Paraguay for its COVID-19 vaccine, part of the island's push ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
